1. Home
  2. HRMY vs ARDT Comparison

HRMY vs ARDT Comparison

Compare HRMY & ARDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • ARDT
  • Stock Information
  • Founded
  • HRMY 2017
  • ARDT 2001
  • Country
  • HRMY United States
  • ARDT United States
  • Employees
  • HRMY N/A
  • ARDT N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • ARDT
  • Sector
  • HRMY Health Care
  • ARDT
  • Exchange
  • HRMY Nasdaq
  • ARDT NYSE
  • Market Cap
  • HRMY 1.6B
  • ARDT 1.7B
  • IPO Year
  • HRMY 2020
  • ARDT 2024
  • Fundamental
  • Price
  • HRMY $34.09
  • ARDT $14.57
  • Analyst Decision
  • HRMY Strong Buy
  • ARDT Buy
  • Analyst Count
  • HRMY 8
  • ARDT 13
  • Target Price
  • HRMY $52.88
  • ARDT $20.69
  • AVG Volume (30 Days)
  • HRMY 729.2K
  • ARDT 299.3K
  • Earning Date
  • HRMY 05-06-2025
  • ARDT 05-06-2025
  • Dividend Yield
  • HRMY N/A
  • ARDT N/A
  • EPS Growth
  • HRMY 13.13
  • ARDT 887.41
  • EPS
  • HRMY 2.62
  • ARDT 1.56
  • Revenue
  • HRMY $744,852,000.00
  • ARDT $6,024,260,000.00
  • Revenue This Year
  • HRMY $20.06
  • ARDT $8.18
  • Revenue Next Year
  • HRMY $18.40
  • ARDT $5.58
  • P/E Ratio
  • HRMY $12.76
  • ARDT $9.52
  • Revenue Growth
  • HRMY 20.62
  • ARDT 8.91
  • 52 Week Low
  • HRMY $26.47
  • ARDT $11.31
  • 52 Week High
  • HRMY $41.61
  • ARDT $20.72
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 69.87
  • ARDT N/A
  • Support Level
  • HRMY $29.82
  • ARDT N/A
  • Resistance Level
  • HRMY $30.61
  • ARDT N/A
  • Average True Range (ATR)
  • HRMY 1.15
  • ARDT 0.00
  • MACD
  • HRMY 0.71
  • ARDT 0.00
  • Stochastic Oscillator
  • HRMY 98.91
  • ARDT 0.00

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About ARDT ARDENT HEALTH PARTNERS INC

Ardent Health Partners Inc is an operator of hospitals and a provider of healthcare services in the United States. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women's services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. The company has one reportable segment: healthcare services that provides healthcare services predominantly through its ownership and operation of hospitals, certain of which provide related healthcare services through physician practices, outpatient centers, and post-acute facilities. Ardent has 30 acute care hospitals, more than 200 sites of care that operate across six states: Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas.

Share on Social Networks: